1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Venus Medtech (Hangzhou) Inc.
  6. News
  7. Summary
    2500   CNE100003PJ8

VENUS MEDTECH (HANGZHOU) INC.

(2500)
  Report
Delayed Hong Kong Stock Exchange  -  04:08 2022-08-17 am EDT
13.78 HKD   -4.31%
07/13China's National Medical Products Administration Approves Venusp-Valve, Venus Medtech's In-House Developed Innovative Transcatheter Pulmonic Valve Replacement System
CI
07/13Chinese Regulator Approves Venus Medtech's Valve Replacement System
MT
06/22First American Patient Treated with VenusP-Valve™ Under Compassionate Use
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Venus Medtech Inc. Appoints Amir Gross as Head of Venus Global Heart Valve Innovation Center

03/01/2022 | 05:00am EDT

Venus Medtech (Hangzhou) Inc. announced that the Venus Global Heart Valve Innovation Center will be established in Israel and Mr. Amir Gross will be appointed as the head of the Venus Global Heart Valve Innovation Center. Mr. Amir Gross is the chief executive officer of Cardiovavlve Ltd. (Cardiovavlve), a pioneering transcatheter mitral and tricuspid valve treatment company, which was 100% acquired by the Company in January 2022.


© S&P Capital IQ 2022
All news about VENUS MEDTECH (HANGZHOU) INC.
07/13China's National Medical Products Administration Approves Venusp-Valve, Venus Medtech's..
CI
07/13Chinese Regulator Approves Venus Medtech's Valve Replacement System
MT
06/22First American Patient Treated with VenusP-Valve™ Under Compassionate Use
AQ
06/22Venus Medtech Inc. Announces First American Patient Treated with VenusP-Valve Under Com..
CI
04/13Venus Medtech Completes First-in-Human Study of Bioprosthetic Heart Valve Product
MT
04/12Venus Medtech Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Comple..
CI
04/12Venus Medtech Wins Approval to Sell Cardiovascular Device in Europe
MT
03/31VENUS MEDTECH ANNOUNCES 2021 ANNUAL : pacesetter in China and breakthrough-maker worldwid..
AQ
03/31Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/21Atom Semiconductor announced that it has received $15.8 million in funding from Gobi Pa..
CI
More news
Financials
Sales 2022 644 M 95,0 M 95,0 M
Net income 2022 -308 M -45,4 M -45,4 M
Net cash 2022 2 543 M 375 M 375 M
P/E ratio 2022 -19,0x
Yield 2022 -
Capitalization 5 217 M 769 M 769 M
EV / Sales 2022 4,15x
EV / Sales 2023 3,02x
Nbr of Employees 905
Free-Float 79,7%
Chart VENUS MEDTECH (HANGZHOU) INC.
Duration : Period :
Venus Medtech (Hangzhou) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VENUS MEDTECH (HANGZHOU) INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 11,91 CNY
Average target price 21,62 CNY
Spread / Average Target 81,4%
EPS Revisions
Managers and Directors
Zhen Jun Zi Executive Director & General Manager
Hai Yue Ma Chief Financial Officer & Joint Secretary
Min Zeng Chairman
Yan Xiao Chairman-Supervisory Board
Hou-Sen Lim Chief Technology & Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
VENUS MEDTECH (HANGZHOU) INC.-53.45%804
STRYKER CORPORATION-16.18%84 804
SMITH & NEPHEW PLC-18.05%11 146
INSPIRE MEDICAL SYSTEMS, INC.-6.35%6 203
AXONICS, INC.29.20%3 554
GLAUKOS CORPORATION18.72%2 510